<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204161</url>
  </required_header>
  <id_info>
    <org_study_id>2019XY-BDB011</org_study_id>
    <nct_id>NCT04204161</nct_id>
  </id_info>
  <brief_title>A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma</brief_title>
  <official_title>A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen BinDeBio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen BinDeBio Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, uni-center, phase I study . In this study, Children
      withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with
      CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">October 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0</measure>
    <time_frame>60 months</time_frame>
    <description>Safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate</measure>
    <time_frame>60 months</time_frame>
    <description>Overall remission rate consists of complete remission rate and partial remission rate of patients being treated with CAR-T19/CAR-T22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR-T cells testing</measure>
    <time_frame>60 months</time_frame>
    <description>The level of CAR-T cells will be tested regularly by Real-time Quantitative Polymerase Chain Reaction Detecting System(qPCR) or Flow cytometry to evaluate the proliferation in vivo and long-term survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood</condition>
  <condition>Refractory B-cell Acute Lymphoblastic Leukemia, Childhood</condition>
  <condition>Relapsed/Refractory B-cell Lymphoma, Childhood</condition>
  <arm_group>
    <arm_group_label>CAR-T19/CAR-T22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T19/CAR-T22</intervention_name>
    <description>According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10^5/kg-2.5x10^8/kg .</description>
    <arm_group_label>CAR-T19/CAR-T22</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with CD19+/CD22+ B cell malignancies who have limited
             prognosis (several months to &lt; 2 year survival) with currently available therapies
             will be enrolled.

               1. no available curative treatment options (such as autologous or allogeneic SCT)

               2. If patients had receive immunotherapy, they should reach requirments:tumor
                  recurrency or the number of B cells recovered.

               3. Patients with recurrence after hematopoietic stem cell transplantation need
                  additional satisfaction: 1) no GvHD and not require immunosuppression;2) stem
                  cell transplantation was completed for at least 4 months, and at least 6 months
                  before the CART reinfusion;

               4. Patients must be willing to sign an informed consent.

               5. Age:≤18 years.

               6. survival&gt;12 weeks

               7. Flow cytometry or IHC showed positive expression of CD19/ CD22 in tumor cells
                  within two months.

               8. Routine blood test:hemoglobin&gt;=90 g/L; platelet&gt;=50×10^9/L.

               9. Liver function: ALT and AST≤2.5 (ULN) times the upper limits of normal (if
                  abnormal liver function is mainly caused by tumor infiltration, it can ≤5 ULN),
                  bilirubin &lt;2.0 mg/dl.

              10. Renal function:BUN: 9-20mg / dl; serum creatinine&lt;= 1.5 times upper limits of
                  normal; endogenous creatinine clearance rate&gt;=50 ml/min

              11. Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV.

              12. Cardiac function: stable hemodynamic and left ventricular ejection fraction
                  (LVEF)&gt;=55%.

              13. ECOG score ≤2。

              14. Adequate venous access for apheresis, and no other contraindications for
                  leukapheresis

        Exclusion Criteria:

          1. ECOG &gt;= 3.

          2. Patients with history of T cell tumors .

          3. organ failure:heart failure Ⅲ and Ⅳ;The liver reached grade C of child-turcotte .Renal
             failure and uremia;Respiratory failure;People with impaired consciousness.

          4. Acute or chronic GVHD after allogeneic hematopoiesis. Hormone or immunosuppressant was
             used within 30 days.

          5. steroid hormoneswere used before and after blood collection and infusion.

          6. HIV infection or active hepatitis B or hepatitis C infection.

          7. Uncontrolled active infection.

          8. Enrolled to other clinical study in the last 4 weeks.

          9. Subjects with systemic auto-immune disease or immunodeficiency.

         10. Allergic to cytokines.

         11. Definite neuropathic or psychotic patients, including authors of dementia or seizures,
             history of psychotropic substance abuse and unable to quit, or other substantial
             lesions that may increase central neurotoxicity.

         12. Patients with malignant tumors of the central nervous system.

         13. Lung, brain or intestinal tumor infiltrates.

         14. The second tumor was found.

         15. Allergic to cytokine antagonists.

         16. Other patients that researchers considered unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Zhonghua</last_name>
    <role>Study Director</role>
    <affiliation>Shenzhen BinDeBio Tech Co.,Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Zhonghua</last_name>
    <phone>18938688105</phone>
    <email>zh.yang@bindebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Minghua, PhD</last_name>
      <phone>13973135843</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

